Mosqueda-Garcia R, Stainback R, Fernandez-Violante R, Hamakubo T
Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
J Cardiovasc Pharmacol. 1995;26 Suppl 3:S159-62.
We studied the cardiovascular effects produced by administration of endothelin-1 (ET-1) into brain nucleic known to affect vasopressin release. In urethane-anesthetized Sprague-Dawley rats, microinjection of ET-1 into the subfornical organ (SFO) resulted in a dose-dependent increase in arterial blood pressure and a decrease in heart rate. These effects were inhibited by previous administration of the ETA receptor antagonist BQ-123 or by intravenous administration of a vasopressin antagonist. In addition, microinjection of ET-1 into the SFO increased plasma levels of vasopressin. In contrast, in the paraventricular nucleus (PVN) of the hypothalamus microinjection of ET-1 evoked a dose-related bradycardia with inconsistent changes in blood pressure. Although the bradycardia was antagonized by intra-PVN administration of BQ-123, the vasopressin antagonist did not affect the changes in heart rate evoked by microinjection of this peptide into the PVN. Overall, these results indicate that the central cardiovascular effects of ET-1 result from activation of several mechanisms, including stimulation of brain centers regulating vasopressin release.
我们研究了向已知影响血管加压素释放的脑核团注射内皮素-1(ET-1)所产生的心血管效应。在乌拉坦麻醉的斯普拉格-道利大鼠中,向穹窿下器(SFO)微量注射ET-1导致动脉血压呈剂量依赖性升高和心率降低。预先给予ETA受体拮抗剂BQ-123或静脉注射血管加压素拮抗剂可抑制这些效应。此外,向SFO微量注射ET-1会使血管加压素的血浆水平升高。相比之下,在下丘脑室旁核(PVN)微量注射ET-1会引起剂量相关的心动过缓,血压变化不一致。虽然PVN内注射BQ-123可拮抗心动过缓,但血管加压素拮抗剂并不影响向PVN微量注射该肽所引起的心率变化。总体而言,这些结果表明ET-1的中枢心血管效应是由多种机制激活所致,包括刺激调节血管加压素释放的脑中枢。